Abstract
Cerebrovascular disease and high blood pressure both appear to increase the risk of vascular dementia. PROGRESS aims to investigate whether blood pressure lowering with an angiotensin coverting enzyme inhibitor-based regimen will reduce the risk of cognitive impairment in patients with a history of stroke or transient ischaemic attack. A total of at least 6000 patients will be randomised to receive perindopril (+/- indapamide) or matching placebo(s), with treatment and follow-up scheduled to continue for at least 4 years. Substudies will investigate the effects of treatment on cognitive decline in subgroups defined by apo-E genotype and on white matter lesions assessed by magnetic resonance imaging. Final results from the study should be available in 2001.
Publication types
-
Clinical Trial
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Angiotensin-Converting Enzyme Inhibitors / pharmacology*
-
Antihypertensive Agents / pharmacology*
-
Blood Pressure / drug effects*
-
Cerebrovascular Disorders / drug therapy*
-
Cerebrovascular Disorders / physiopathology
-
Cerebrovascular Disorders / psychology
-
Clinical Protocols
-
Dementia, Vascular / physiopathology
-
Dementia, Vascular / prevention & control*
-
Diuretics / pharmacology
-
Female
-
Humans
-
Indapamide / pharmacology
-
Indoles / pharmacology*
-
Ischemic Attack, Transient / drug therapy
-
Ischemic Attack, Transient / physiopathology
-
Ischemic Attack, Transient / psychology
-
Male
-
Middle Aged
-
Perindopril
Substances
-
Angiotensin-Converting Enzyme Inhibitors
-
Antihypertensive Agents
-
Diuretics
-
Indoles
-
Indapamide
-
Perindopril